In women with locally advanced cervical cancer, additional chemotherapy after standard chemoradiation does not improve survival and is associated with side effects, according to results from the phase 3 OUTBACK trial.
The findings are likely to change practice for clinicians who have been providing the additional chemotherapy in the hope that it would improve outcomes.
With the standard treatment for locally advanced cervical cancer—chemoradiation with cisplatin-based chemotherapy